KR100693796B1 - 항종양제 및 적혈구용적 증강제의 조합체 - Google Patents

항종양제 및 적혈구용적 증강제의 조합체 Download PDF

Info

Publication number
KR100693796B1
KR100693796B1 KR1020017012929A KR20017012929A KR100693796B1 KR 100693796 B1 KR100693796 B1 KR 100693796B1 KR 1020017012929 A KR1020017012929 A KR 1020017012929A KR 20017012929 A KR20017012929 A KR 20017012929A KR 100693796 B1 KR100693796 B1 KR 100693796B1
Authority
KR
South Korea
Prior art keywords
epo
cisplatin
erythropoietin
tumor
antitumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017012929A
Other languages
English (en)
Korean (ko)
Other versions
KR20020000557A (ko
Inventor
엠. 스티븐 피버
데이비드 에프. 실버
Original Assignee
헬스 리서치 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 헬스 리서치 인코포레이티드 filed Critical 헬스 리서치 인코포레이티드
Publication of KR20020000557A publication Critical patent/KR20020000557A/ko
Application granted granted Critical
Publication of KR100693796B1 publication Critical patent/KR100693796B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
KR1020017012929A 1999-04-27 2000-04-24 항종양제 및 적혈구용적 증강제의 조합체 Expired - Fee Related KR100693796B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/300,124 1999-04-27
US09/300,124 US6171620B1 (en) 1999-04-27 1999-04-27 Method of enhancing the efficacy of anti-tumor agents
PCT/US2000/011000 WO2000064455A1 (en) 1999-04-27 2000-04-24 Method of enhancing the efficacy of anti-tumor agents

Publications (2)

Publication Number Publication Date
KR20020000557A KR20020000557A (ko) 2002-01-05
KR100693796B1 true KR100693796B1 (ko) 2007-03-12

Family

ID=23157813

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017012929A Expired - Fee Related KR100693796B1 (ko) 1999-04-27 2000-04-24 항종양제 및 적혈구용적 증강제의 조합체

Country Status (18)

Country Link
US (3) US6171620B1 (enExample)
EP (1) EP1212068A4 (enExample)
JP (1) JP2002542296A (enExample)
KR (1) KR100693796B1 (enExample)
CN (1) CN1188137C (enExample)
AU (1) AU781301B2 (enExample)
BG (1) BG64940B1 (enExample)
BR (1) BR0010082A (enExample)
CA (1) CA2368618C (enExample)
HU (1) HUP0200840A3 (enExample)
IL (1) IL146012A0 (enExample)
MX (1) MXPA01010899A (enExample)
NO (1) NO20015227L (enExample)
NZ (1) NZ514521A (enExample)
PL (1) PL350918A1 (enExample)
RU (1) RU2271829C2 (enExample)
WO (1) WO2000064455A1 (enExample)
ZA (1) ZA200108012B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
IL152428A0 (en) 2000-04-26 2003-05-29 Univ Kingston Formulations and method of using nitric oxide mimetics against a malignant cell phenotype
US20050142217A1 (en) * 2000-04-26 2005-06-30 Adams Michael A. Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
ATE466085T1 (de) * 2002-09-09 2010-05-15 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
ES2528669T3 (es) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
DE10361813A1 (de) * 2003-12-30 2005-09-08 Bionethos Holding Gmbh Verfahren zur Regeneration von Gewebe
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CA2600350C (en) * 2005-03-07 2015-02-10 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
JP2010510794A (ja) 2006-11-28 2010-04-08 ハナル ファーマシューティカル カンパニー リミテッド 修飾型エリスロポエチンポリペプチド及びこの治療用用途
MX2009010515A (es) 2007-03-29 2009-10-19 Wyeth Corp Antagonistas del receptor opioide periferico y usos de los mismos.
EP3263571B2 (en) 2007-03-29 2023-08-23 Progenics Pharmaceuticals, Inc. Crystal form of (r)-n-methylnaltrexone bromide and uses thereof
JP5461386B2 (ja) 2007-03-29 2014-04-02 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 末梢オピオイド受容体アンタゴニストおよびその使用
US8471022B2 (en) 2008-02-06 2013-06-25 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone
US8685995B2 (en) 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CA2723621A1 (en) * 2008-05-15 2009-11-19 Edison Pharmaceuticals, Inc Treatment of hearing and balance impairments using compounds having erythropoietin activity
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
PL230756B1 (pl) * 2015-09-11 2018-12-31 Univ Medyczny W Bialymstoku Erytropoetyna oraz inhibitor kinazy Brutona w postaci 2- cyjan o-N-( 2,5-dibromofenylo)- 3-hydroksy-2- butenamidu do zastosowania jako lek oraz ich zastosowanie do wytwarzania leku do terapii nowotworu
JPWO2019083023A1 (ja) * 2017-10-26 2020-11-12 国立大学法人 筑波大学 癌の治療に使用するための組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
JP2632014B2 (ja) * 1988-03-03 1997-07-16 中外製薬株式会社 骨髄機能障害性貧血治療剤
RU2111750C1 (ru) * 1995-02-23 1998-05-27 Институт элементоорганических соединений РАН Модификатор для противоопухолевой терапии
JPH1067678A (ja) * 1996-06-20 1998-03-10 Chugai Pharmaceut Co Ltd 肝疾患治療用医薬組成物
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury

Also Published As

Publication number Publication date
CA2368618A1 (en) 2000-11-02
US6171620B1 (en) 2001-01-09
HUP0200840A3 (en) 2003-04-28
US6620779B2 (en) 2003-09-16
US20010000730A1 (en) 2001-05-03
CN1352561A (zh) 2002-06-05
CN1188137C (zh) 2005-02-09
PL350918A1 (en) 2003-02-10
RU2271829C2 (ru) 2006-03-20
MXPA01010899A (es) 2003-06-24
AU4486300A (en) 2000-11-10
CA2368618C (en) 2011-03-01
AU781301B2 (en) 2005-05-12
NO20015227L (no) 2001-12-27
BR0010082A (pt) 2002-01-15
KR20020000557A (ko) 2002-01-05
HUP0200840A2 (hu) 2002-07-29
NZ514521A (en) 2003-07-25
BG106057A (en) 2002-04-30
BG64940B1 (bg) 2006-10-31
NO20015227D0 (no) 2001-10-25
EP1212068A4 (en) 2007-03-14
US6426094B2 (en) 2002-07-30
JP2002542296A (ja) 2002-12-10
ZA200108012B (en) 2003-03-26
IL146012A0 (en) 2002-07-25
US20020198153A1 (en) 2002-12-26
EP1212068A1 (en) 2002-06-12
WO2000064455A1 (en) 2000-11-02

Similar Documents

Publication Publication Date Title
KR100693796B1 (ko) 항종양제 및 적혈구용적 증강제의 조합체
Weiss New insights into erythropoietin and epoetin alfa: mechanisms of action, target tissues, and clinical applications
HU230273B1 (hu) Egy epotilon analóg és kemoterápiás szerek kombinációja proliferatív betegségek kezelésére
Kadhim et al. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (β-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models
EP4424310B1 (en) Anti-tumor pharmaceutical composition comprising azvudine and an egfr/tki inhibitor
EP0488718A2 (en) Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
Strander Interferons and osteosarcoma
JP4980236B2 (ja) Ｖｅｇｆ阻害剤および５ｆｕまたはこの誘導体の１つを含有する抗腫瘍組合せ物
Valadares et al. The effect of a titanocene dichloride derivative, Ti IV (C5H5) 2 NCS2, on the haematopoietic response of Ehrlich tumour-bearing mice
Amagase et al. Epidermal growth factor receptor‐mediated selective cytotoxicity of antitumor agents toward human xenografts and murine syngeneic solid tumors
DE112020003610T5 (de) Neue anwendungen von phenothiazinen oder ihren verbindungen ähnlicher struktur in der pharmazeutik
WO2020226526A1 (en) Method for increasing cancer patient's haemoglobin level
Tsavaris et al. Concomitant administration of 4-hydroxypyrazolopyrimidine (allopurinol) and high-dose continuous infusion 5-fluorouracil
CN112168971B (zh) 抗vegf抗体和pdgf/pdgfr抑制剂在制备治疗表达fgf2肿瘤的药物的应用
WO2025245688A1 (zh) 聚乙二醇修饰白介素2的抗肿瘤效应及其免疫机制
KR20250080866A (ko) C/ebp-베타 길항제 및 면역조절제의 용도
KR101285470B1 (ko) ＴＮＦ－α를 발현하는 살모넬라를 포함하는 항암치료 보조제
KR20210151528A (ko) Ｉｌ-２ 단백질 및 ｃｄ８０ 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물
Shi et al. Experimental study on effect of recombinant human growth hormone combined with chemotherapy on stomach neoplasms implanted in nude mice
CN117398467A (zh) 一种预防或治疗滤泡淋巴瘤的联合用药物组合物及其应用
Gunther Biotherapy of Breast Cancer with EGF-Genistein
Zeren Biotherapy of breast cancer with genistein targeted by epidermal growth factor
KR20100016392A (ko) 암의 치료에 기여하는 조성물 및 방법
KR20100131457A (ko) 시티딘 유도체 및 카르보플라틴을 함유하는 항종양제
HK1150151A (en) Anti-tumor agent comprising cytidine derivative and carboplatin

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20100108

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20110307

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20110307

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000